TNF-α as therapeutic target in NASH: Tried, but not yet proven

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 5, 2007, Pages 613-614

  Chitturi, Shivakumar ^a   Farrell, Geoffrey C ^a  

^a CANBERRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIINFECTIVE AGENT; BETAINE; BEZAFIBRATE; LOSARTAN; METFORMIN; PENTOXIFYLLINE; PLACEBO; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID;

BARIATRIC SURGERY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EDITORIAL; ENDOTOXEMIA; FATTY ACID OXIDATION; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; LIVER BIOPSY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 34247205219     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.04953.x     Document Type: Editorial

References (24)

1. Chitturi S, Farrell GC, Hashimoto E et al. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J. Gastroenterol. Hepatol. 2007 (in press).
2. Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH. Which is the best target to treat? J. Hepatol. 2006; 44: 253-61.
3. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-19.
4. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 2005; 42: 132-8.
5. Hui JM, Kench JG, Chitturi S et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38: 420-7.
6. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.
7. Day CP, James OF. Steatohepatitis: a tale of two 'hits'? Gastroenterology 1998; 114: 842-5.
8. Angulo P. Management of NASH: current and future perspectives. In: Farrell GC, Hall PM, George J, McCullough AJ, eds. Fatty Liver Disease. NASH and Related Conditions. Malden, MA: Blackwell Publishing, 2005; 194-207.
9. Lindor KD, Kowdley KV, Heathcote EJ et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-8.
10. Klein S, Mittendorfer B, Eagon JC et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006; 130: 1564-72.
11. McCullough AJ. Thiazolidinediones for nonalcoholic steatohepatitis- promising but not ready for prime time. N. Engl. J. Med. 2006; 355: 2361-3.
12. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst. Rev. 2007; 1: CD005166.
13. Loomba R, Lutchman G, Kleiner D et al. Pilot study of metformin in patients with nonalcoholic steatohepatitis. Hepatology 2006; 44: 260A.
14. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH. TNF-α or adiponectin? Hepatology 2004; 40: 46-54.
15. Dela Pena A, Leclercq I, Field J, George J, Jones B, Farrell G. NF-κB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 2005; 129: 1663-74.
16. Deng QG, She H, Cheng JH et al. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 2005; 42: 905-14.
17. Windmeier C, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen. Pharmacol. 1997; 29: 181-96.
18. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-164.
19. Desmouliere A, Xu G, Costa AM, Yousef IM, Gabbiani G, Tuchweber B. Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells. J. Hepatol. 1999; 30: 621-31.
20. Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J. Hepatol. 2004; 41: 592-8.
21. Satapathy SK, Garg S, Chauhan R et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2004; 99: 1946-52.
22. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2004; 99: 2365-8.
23. Lee YM, Sutedja D, Wai CT et al. A randomised controlled double blind study of pentoxifylline in patients with nonalcoholic steatohepatitis. Hepatology 2006; 44: 654A.
24. Chan HL-Y, de Silva HJ, Leung NW-Y, Lim S-G, Farrell GC and the Asia-Pacific Working Party on NAFLD. How should we manage patients with non-alcoholic fatty liver disease? J. Gastroenterol. Hepatol. 2007 (in press).